Capitalization 10.81B 9.29B 8.62B 8.05B 14.99B 983B 16.11B 99.56B 39.21B 468B 40.55B 39.72B 1,710B P/E ratio 2025 *
52.4x
P/E ratio 2026 * 30.3x
Enterprise value 12.74B 10.95B 10.16B 9.49B 17.67B 1,158B 18.98B 117B 46.22B 551B 47.79B 46.81B 2,015B EV / Sales 2025 *
3.18x
EV / Sales 2026 * 3.03x
Free-Float
97.96%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
01-16 Citigroup Adjusts Price Target on Charles River Laboratories International to $265 From $200, Maintains Buy Rating MT
01-13 Charles River Laboratories International, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 10:30 AM
01-13 Charles River Laboratories International Seeks Acquisitions CI
01-13 Baird Adjusts PT on Charles River Laboratories International to $231 From $224, Keeps Outperform Rating MT
01-13 Evercore ISI Adjusts PT on Charles River Laboratories International to $260 From $250, Maintains Outperform Rating MT
01-12 Charles River Laboratories Reports Two Planned Acquisitions; Names Namandje Bumpus as Chief Scientific and Innovation Officer MT
01-12 Charles River to buy Cambodia-based monkey supplier for $510 million RE
01-12 Charles River Laboratories provides business updates RE
01-12 Charles River Laboratories Names Dr. Namandjé N. Bumpus as Senior Vice President, Chief Scientific and Innovation Officer CI
01-11 Charles River Laboratories International, Inc. exercised its option to acquire remaining 79% stake in PathoQuest SAS for ?51.6 million. CI
01-11 Charles River Laboratories International, Inc. entered into agreement to acquire Assets of K.F. Ltd. from K.F. Ltd. for $510 million. CI
01-11 Charles River Laboratories International, Inc. entered into agreement to acquire Assets of K.F. Ltd. from K.F. Ltd. for $510 million. CI
01-09 Mizuho Adjusts Price Target on Charles River Laboratories International to $215 From $200, Maintains Neutral Rating MT
More news
1 day-1.69%
1 week+0.40%
Current month+10.14%
1 month+11.49%
3 months+23.07%
6 months+42.22%
Current year+10.14%
More quotes
1 week 214.11
Extreme 214.11
227.5
1 month 194.93
Extreme 194.93
228.88
Current year 194.93
Extreme 194.93
228.88
1 year 91.86
Extreme 91.8609
228.88
3 years 91.86
Extreme 91.8609
275
5 years 91.86
Extreme 91.8609
460.21
10 years 65.7
Extreme 65.7
460.21
More quotes
Manager TitleAgeSince
Chief Executive Officer 75 31/12/1991
Director of Finance/CFO 49 28/09/2025
Chief Tech/Sci/R&D Officer 45 11/01/2026
Director TitleAgeSince
Chairman 75 31/12/1999
Director/Board Member 69 04/07/2017
Director/Board Member 70 30/09/2019
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.69%+0.40%+34.37%-5.92% 10.81B
-2.36%-3.50%-3.05%+11.52% 48.93B
-1.49%-1.32%+20.43%+6.92% 40.48B
-0.03%+1.26%+60.98%+23.20% 37.42B
-0.71%-3.69%+20.76%+39.16% 31.03B
-2.43%+2.65%+198.54%+335.64% 23.25B
-1.16%+1.95%+81.09%+166.96% 17.21B
Average -1.41%+0.04%+59.02%+82.50% 29.88B
Weighted average by Cap. -1.40%-0.13%+47.75%+64.75%
See all sector performances

Financials

2025 *2026 *
Net sales 4.01B 3.44B 3.19B 2.98B 5.55B 364B 5.97B 36.89B 14.53B 173B 15.02B 14.72B 633B 4.08B 3.5B 3.25B 3.03B 5.65B 370B 6.07B 37.53B 14.78B 176B 15.29B 14.97B 644B
Net income 215M 185M 171M 160M 298M 19.53B 320M 1.98B 780M 9.3B 806M 790M 33.99B 381M 327M 304M 284M 528M 34.62B 567M 3.51B 1.38B 16.48B 1.43B 1.4B 60.23B
Net Debt 1.93B 1.66B 1.54B 1.44B 2.68B 176B 2.88B 17.79B 7.01B 83.58B 7.24B 7.1B 305B 1.54B 1.32B 1.23B 1.15B 2.14B 140B 2.3B 14.19B 5.59B 66.67B 5.78B 5.66B 244B
More financial data * Estimated data
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (60.5%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (20.5%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (81.6%) and sales of products (18.4%). Net sales are distributed geographically as follows: the United States (55.3 Europe (26.6%), Canada (11.9%), Asia/Pacific (4.9%) and other (1.3%).
Employees
19,400
More about the company
Date Price Change Volume
16/01/26 219.70 $ -1.69% 866,972
15/01/26 223.47 $ +3.27% 779,526
14/01/26 216.39 $ -1.19% 936,397
13/01/26 218.99 $ +0.08% 1,054,449

Delayed Quote Nyse, January 16, 2026 at 09:00 pm

More quotes
Trader
Investor
Global
Quality
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
219.70USD
Average target price
209.64USD
Spread / Average Target
-4.58%
Consensus

Quarterly revenue - Rate of surprise